9-azabicyclo'3.3.1!non-6-ee derivatives with a heteroatom at the 3-position as renin inhibitors

Details for Australian Patent Application No. 2004233575 (hide)

Owner Actelion Pharmaceuticals Ltd

Inventors Richard-Bildstein, Sylvia; Bur, Daniel; Fischli, Walter; Sifferlen, Thierry; Weller, Thomas; Bezencon, Oliver; Remen, Lubos

Agent A J Park

Pub. Number AU-A-2004233575

PCT Pub. Number WO2004/096366

Priority PCT/EP03/04492 30.04.03 EP

Filing date 26 April 2004

Wipo publication date 11 November 2004

International Classifications

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

C07D 498/08 (2006.01) Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms

C07D 513/08 (2006.01) Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or

A61K 31/5386 (2006.01)

A61K 31/547 (2006.01) - spiro-condensed or forming part of bridged ring systems

Event Publications

15 December 2005 PCT application entered the National Phase

  PCT publication WO2004/096366 Priority application(s): WO2004/096366

7 February 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004233576-Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis

2004233572-Pharmaceutical composition in the form of a hydrogel for transdermal administration of active substances